Avaliação do risco cardiovascular por meio do índice LAP em pacientes não obesas com síndrome dos ovários policísticos

Costa, Eduardo Caldas; Sá, Joceline Cássia Ferezini de; Soares, Elvira Maria Mafaldo; Lemos, Telma Maria Araújo Moura; Maranhão, Técia Maria de Oliveira; Azevedo, George Dantas de

doi:10.1590/s0004-27302010000700007

Cited by 9 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 The LAP index may thus constitute an abdominal adiposity marker that correlates with central lipid accumulation. 8 Since the LAP index was first proposed, in Kahn's pioneering study, 9 many researchers have used it to predict cardiovascular risk in different populations, such as among patients with type 2 diabetes 6 or insulin resistance, 10 women with polycystic ovarian syndrome 10,11 and hospital outpatients 12 and inpatients. 7 However, no studies have evaluated the use of this index among patients attending primary care units.…”

Section: Introductionmentioning

confidence: 99%

Cardiovascular risk assessment using the lipid accumulation product index among primary healthcare users: a cross-sectional study

et al. 2019

View full text Add to dashboard Cite

BACKGROUND: The lipid accumulation product (LAP) index is an abdominal adiposity marker. OBJECTIVE: The aim of this study was to describe the cardiovascular risk of primary healthcare users through the LAP index and correlate it with anthropometric and biochemical indicators. DESIGN AND SETTING: Cross-sectional study in primary care units in a city in northeastern Brazil. METHODS: The subjects responded to a structured questionnaire that contained questions about their sociodemographic condition, and then underwent an anthropometric nutritional assessment. The LAP index values were expressed as three degrees of cardiovascular risk intensity: high risk (above the 75 th percentile), moderate risk (between the 25 th and 75 th percentiles) and low risk (below the 25 th percentile). RESULTS: The median LAP index was 52.5 cm.mmol/l (range: 28.2-86.6), and there was no statistically significant difference between the sexes: 57.7 cm.mmol/l (24.5-91.1) and 49.5 cm.mmol/l (29.8-85.2) for females and males, respectively (P = 0.576). Among all the subjects, 67.2% were overweight and there was a statistically significant difference in mean LAP index between those who were and those who were not overweight. Statistically significant differences in anthropometric and biochemical markers for cardiovascular risk were observed among individuals who had higher LAP index values. There were significant correlations between the LAP index and all of the biochemical variables. CONCLUSIONS: These significant correlations between the LAP index and the traditional biochemical risk markers may be useful within conventional clinical practice, for cardiovascular risk screening in primary healthcare.

show abstract

Section: Introductionmentioning

confidence: 99%

Cardiovascular risk assessment using the lipid accumulation product index among primary healthcare users: a cross-sectional study

et al. 2019

View full text Add to dashboard Cite

show abstract

Increased 10-year cardiovascular disease and mortality risk scores in asymptomatic patients with calcium oxalate urolithiasis

et al. 2011

View full text Add to dashboard Cite

Both the prevalence of cardiovascular risk factors and event rate are increased in patients with urolithiasis. Screening is recommended to all patients who have high cardiovascular risk. The aim of this study was to document 10-year risk of cardiovascular disease and mortality in asymptomatic patients with urolithiasis. Consecutive 200 patients with calcium oxalate urolithiasis were compared with 200 age- and sex-matched healthy controls. Ten-year cardiovascular disease risk was calculated with the Framingham Risk Score and mortality risk with SCORE risk score. Calcium, oxalate, and citrate excretion were studied as urinary stone risk factors. The results indicate that patients with urolithiasis had higher total cholesterol (p < 0.0001), lower HDL-cholesterol (p < 0.0001), and higher systolic blood pressure (p < 0.0001) and hsCRP (p < 0.0001) compared with controls. Patients with urolithiasis had a higher Framingham Risk Scores [OR 8.36 (95% CI 3.81-18.65), p = 0.0001] and SCORE risk score [OR 3.02 (95% CI 1.30-7.02), p = 0.0006] compared with controls. The Framingham and SCORE risk score were significantly correlated with urinary calcium (p = 0.0001, r = 0.460, and p = 0.005, r = 0.223, respectively) and oxalate excretion (p = 0.0001, r = 0.516, p = 0.001, r = 0.290, respectively). In multiple linear regression analysis, urinary calcium and oxalate excretion, age, sex, total cholesterol, HDL-cholesterol, hsCRP and smoking were the independent predictors of 10-year cardiovascular disease risk and urinary calcium and oxalate excretion, age, sex, total cholesterol, fasting blood glucose for 10-year cardiovascular mortality. In conclusion, patients with calcium oxalate urolithiasis carry high risk of cardiovascular disease and mortality. All patients should be screened at the initial diagnosis of urolithiasis for the risk factors.

show abstract

Elevation of isoprostanes in polycystic ovary syndrome and its relationship with cardiovascular risk factors

Calzada

López-Riquelme

Noguera

et al. 2018

J Endocrinol Invest

View full text Add to dashboard Cite

show abstract

Avaliação do risco cardiovascular por meio do índice LAP em pacientes não obesas com síndrome dos ovários policísticos

Cited by 9 publications

References 29 publications

Cardiovascular risk assessment using the lipid accumulation product index among primary healthcare users: a cross-sectional study

Cardiovascular risk assessment using the lipid accumulation product index among primary healthcare users: a cross-sectional study

Increased 10-year cardiovascular disease and mortality risk scores in asymptomatic patients with calcium oxalate urolithiasis

Elevation of isoprostanes in polycystic ovary syndrome and its relationship with cardiovascular risk factors

Contact Info

Product

Resources

About